Sponsor
Gabe Evans
Representative · R-CO
Representative · R-CO
The bill strengthens legal definitions, enforcement coordination, data transparency, and prevention campaigns to reduce overdoses from counterfeit fentanyl and meth—at the cost of raising criminal liability risks for users and some businesses and imposing new resource and reporting burdens on agencies and taxpayers.
People at risk of accidentally ingesting counterfeit pills (youth, patients with chronic conditions, and the general public) will face lower overdose risk because the law defines fentanyl- or meth-containing lookalike pills as "counterfeit," strengthens interdiction and prosecutions, and funds data-driven public-awareness and prevention efforts.
Law enforcement and prosecutors will have clearer legal authorities, statutory language, coordinated strategies, and data to investigate, seize, and prosecute sellers and traffickers of counterfeit fentanyl and methamphetamine, improving interdiction outcomes.
Local governments, schools, and nonprofits will receive targeted, audited, and data-informed public-awareness campaigns and youth prevention programs aimed at reducing exposure to counterfeit fentanyl and methamphetamine.
People who use drugs (including low-income individuals and some youth) face heightened risk of criminalization and increased prosecutions because broader counterfeit definitions and stronger enforcement make possession or distribution easier to charge even when intent is unclear.
Manufacturers, distributors, pharmacies, and other entities that handle legitimate products could face expanded criminal liability, higher compliance costs, and litigation risk if packaging similarities are ambiguous or prohibitions are broadened.
Strengthening enforcement, running audited awareness campaigns, and compiling required reports will impose additional DEA/DOJ/ONDCP resource needs and administrative burdens that could increase costs to taxpayers or divert staff from frontline work.
Based on analysis of 5 sections of legislative text.
Defines counterfeit fentanyl/methamphetamine pills, expands a criminal statute's scope, requires a DEA response plan within 180 days, and mandates annual DOJ reports on seizures and prosecutions.
Official title: To amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
Introduced March 19, 2026 by Gabe Evans · Last progress March 19, 2026
Creates a federal response to counterfeit pill threats by defining "counterfeit fentanyl or methamphetamine substance," expanding criminal statute language, requiring the DEA to produce an operational plan within 180 days to strengthen investigations, seizures, prevention and public-awareness efforts, and directing DOJ (with DEA and ONDCP) to provide annual reports to Congress on seizures, identifications, prosecutions, and prevention activities. The annual report must include aggregated seizure and lab-identification data, pill-form breakdowns, spatial and temporal seizure patterns, charging and conviction data (with narrow nondisclosure exceptions), and descriptions of prevention and awareness efforts.